Cadila Healthcare

Global Pharmaceutical Drugs Industry Report 2022: Featuring Abbott, Dr. Reddy's Laboratories, GlaxoSmithKline, Pfizer, Sanofi, Takeda Pharmaceutical and Zydus Cadila - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 26, 2022
Health, Pharmaceutical, Laboratory, Government, Biopharmaceutical, Intelligence, Research, Pfizer, Goal, GlaxoSmithKline, Cadila Healthcare, Environment, COVID-19, Medical device, Pharmaceutical industry, Fine chemical, Generic drug

This research report incorporates an in-depth analysis of the pharmaceutical drugs market and its competitive landscape through 2021.

Key Points: 
  • This research report incorporates an in-depth analysis of the pharmaceutical drugs market and its competitive landscape through 2021.
  • The goals and objectives of this study include:
    Defining and discussing the competitive landscape of the global pharmaceutical drugs market in 2021.
  • Tracking alliances, joint ventures, mergers and acquisitions, new product development and R&D in the global pharmaceutical drugs market.
  • Chapter 5 Pricing and Reimbursement: Pharmaceuticals and Biologics
    Chapter 6 Pharmaceutical Drugs Industry: Competitive Landscape
    A. Menarini Industrie Farmaceutiche Riunite S.R.L.

PharmaJet to Present Latest Research Showing Superior Immunogenicity with Their Needle-free Systems at Five Conferences in October

Retrieved on: 
Tuesday, September 27, 2022
Biotechnology, Pharmaceutical, Medical Supplies, Health, Medical Devices, Infectious Diseases, Clinical Trials, Other Health, Adult, Therapy, Volunteering, Injection, COVID-19, Protamine, RNA transfection, Plasmid, Needle, ID, N/S, Electroporation, Vaccination, Review, Tropy, Cadila Healthcare, Use, Vaccine

Intradermal Needle-free delivered vaccines can induce strong immune response comparable to intramuscular and subcutaneous injection with a fraction of the dose.

Key Points: 
  • Intradermal Needle-free delivered vaccines can induce strong immune response comparable to intramuscular and subcutaneous injection with a fraction of the dose.
  • The presentations may also include data from collaborations including those with:
    1.
  • 3 The low dose Tropis group produced significantly increased B and T cell responses compared to a higher dose IM N/S vaccination.
  • Refer to Instructions for Use to ensure safe injections and to review risks.

Global Branded Generics Market Report 2022: Growing Potential in Emerging Markets Creates Opportunities - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 21, 2022
Health, Pharmaceutical, Aurobindo Pharma, Cancer, Risk, Cipla, Geography, Growth, Market share, Ansoff Matrix, Industry, Market development, USD, Investment, Others, Laboratory, AstraZeneca, Cadila Healthcare, Amneal Pharmaceuticals, CNS, Bausch Health, SWOT, Hospital pharmacy, CAGR, Retail, Marketing, Apotex, Pharmacy

The Global Branded Generics Market is segmented based on Product, Applications, Distribution Channel, and Geography.

Key Points: 
  • The Global Branded Generics Market is segmented based on Product, Applications, Distribution Channel, and Geography.
  • The report presents a detailed Ansoff matrix analysis for the Global Branded Generics Market.
  • The Global Branded Generics Market is analyzed using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • Based on the SWOT analysis conducted on the industry and industry players, suitable strategies have been devised for market growth.

Ki Young Sohn, CEO of Enzychem Lifesciences Honored by World Biz Magazine Leadership Awards With 'Top 100 Innovation CEO' Award

Retrieved on: 
Wednesday, May 11, 2022
COVID-19, WBM, Culture, GLOBE, KOSDAQ, Patient, Partnership, Inflammation, Cancer, Social responsibility, Therapy, Industry, Leadership, Vaccination, CEO, Research, Interview, Growth, Heart, Cadila Healthcare, Plasmid, Homeostasis, ESG, Pharmaceutical industry

LONDON, May 11, 2022 (GLOBE NEWSWIRE) -- Ki Young Sohn is Chairman and CEO of Enzychem Lifesciences, a late-stage biotechnology company.

Key Points: 
  • LONDON, May 11, 2022 (GLOBE NEWSWIRE) -- Ki Young Sohn is Chairman and CEO of Enzychem Lifesciences, a late-stage biotechnology company.
  • Founded in 1999, Enzychem Lifesciences is developing novel small molecule therapeutics to target fundamental pathways in inflammation, for patients with unmet needs.
  • KiYoung Sohn was also interviewed in World Biz Magazine where he shared insights into Enzychem Lifesciences' missionandfactorsdriving thecompany'srapid growth.
  • "It is a great honor to receive World Biz Magazine's 'Top 100 Innovation CEO' Award.

Sentynl Therapeutics Announces Continued Availability of NULIBRY® (fosdenopterin) and the Launch of Sentynl Cares™ Patient Access Program.

Retrieved on: 
Monday, April 25, 2022
Degenerative disease, Use, Diagnosis, MRI, Collection, Life, Caregiver, Brain damage, Red, Neurotoxicity, Patient, Dysphagia, Molybdenum, Magnetic resonance imaging, FDA, Pneumonia, Fosdenopterin, Therapy, Surge arrester, Sulfite oxidase, Molybdenum cofactor deficiency, Food, Incidence, Compliance, Fever, Freedom, Otitis media, Mortality, Environment, Encephalopathy, Disease, Photosensitivity, Retard (pejorative), Cadila Healthcare, Rash, Sulfite, Skin, CPMP, Seizure, SPF, Vomiting, Blister, Prevalence, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Brain, MOCS1, Sunlight, Warning, Otitis, Metabolism, Injection, Risk, Forecasting, Pharmaceutical industry, Medical device, Hospital

Sentynl Cares provides a comprehensive set of support programs dedicated to helping children with MoCD Type A in the United States gain access to NULIBRY.

Key Points: 
  • Sentynl Cares provides a comprehensive set of support programs dedicated to helping children with MoCD Type A in the United States gain access to NULIBRY.
  • Sentynl Therapeutics Announces Continued Availability of NULIBRY (fosdenopterin) and Launch of Sentynl Cares Program.
  • Launching Sentynl Cares a comprehensive set of support programs dedicated to helping children get access to our therapies.
  • Sentynl Cares also provides tools and resources to help facilitate the access process.

PharmaJet partner Zydus Cadila Announces COVID-19 Vaccine Expansion Plan to Multiple Countries With Korean Firm

Retrieved on: 
Tuesday, January 4, 2022
Medical Devices, Infectious Diseases, Health, Pharmaceutical, Medical Supplies, Policy, Organic acid, COVID-19, Vaccine, U.S. FDA, Review, Therapy, Cadila Healthcare, Patient, DNA, Cancer, CE marking, US FDA, US, COVID, Degenerative disease, CEO, R & D, LinkedIn, Immunization, Inflammation, Partnership, Polio, System, Use, Certification, Technology, WHO, EUA, Injection, PQS, COVID 19, Pharmaceutical industry, PharmaJet, Enzychem, Zydus, PHARMAJET, ENZYCHEM, ZYDUS

PharmaJet , the maker of innovative, needle-free injection technology, today announced that its partner Zydus Cadila , is partnering with Enzychem Lifesciences to manufacture their COVID-19 plasmid DNA vaccine (ZyCoV-D) in Korea.

Key Points: 
  • PharmaJet , the maker of innovative, needle-free injection technology, today announced that its partner Zydus Cadila , is partnering with Enzychem Lifesciences to manufacture their COVID-19 plasmid DNA vaccine (ZyCoV-D) in Korea.
  • The vaccine will be manufactured in Korea and exported to several lower-middle income countries in Latin America and Asian New Southern Policy member countries.
  • Under the terms of this agreement, Zydus will transfer its manufacturing technology and provide technical assistance to Enzychem Lifesciences.
  • The vaccine is administered intradermally using the PharmaJet needle-free system, which can be deployed more readily, especially in resource-poor populations where these are urgently needed.

Adalimumab, Infliximab and Etanercept Biosimilars Global Market Research Report 2021 Featuring Zydus Cadila, Sandoz, Samsung Bioepis, AbbVie, Amgen, Boehringer Ingelheim, Pfizer, Celltrion, and Mylan - ResearchAndMarkets.com

Retrieved on: 
Friday, December 10, 2021
Health, Pharmaceutical, Celltrion, Hospira, COVID-19, Patent, Royal commission, Amgen, FDA, Infliximab, Crohn's disease, Application, Ankylosing spondylitis, European Commission, AbbVie, SPCS, Safety, Ulcerative colitis, Growth, Psoriatic arthritis, Degenerative disease, Mylan, Rheumatoid arthritis, Adult, Psoriasis, Pharmacy, Cadila Healthcare, Boehringer Ingelheim, Animal, Fine chemical, Generic drug, Pharmaceutical industry

Major players in the adalimumab, infliximab and etanercept biosimilars market are Zydus Cadila, Sandoz (Novartis), Samsung Bioepis, AbbVie, Amgen, Boehringer Ingelheim, Pfizer, Celltrion, and Mylan.

Key Points: 
  • Major players in the adalimumab, infliximab and etanercept biosimilars market are Zydus Cadila, Sandoz (Novartis), Samsung Bioepis, AbbVie, Amgen, Boehringer Ingelheim, Pfizer, Celltrion, and Mylan.
  • The adalimumab, infliximab and etanercept biosimilars market consists of sales of adalimumab, infliximab and etanercept biosimilar drugs by the companies that manufacture these biosimilars.
  • The adalimumab, infliximab and etanercept biosimilars market covered in this report is segmented by product into adalimumab biosimilars (exemptia, mabura, hyrimoz, hadlima, abrilada, others), infliximab biosimilars (inflectra, renflexis, ixifi, avsola), cipleumab (erelzi, eticovo).
  • Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
    6.2.

Enzychem to Partner with Zydus Cadila to Manufacture COVID-19 Plasmid DNA Vaccine in Korea

Retrieved on: 
Friday, November 26, 2021
Science, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Genetics, Clinical Trials, Transfer, Policy, Patient, Plasmid, Developing country, Technology, Partnership, CHL, Cancer, Clinical trial, Inflammation, Human, KOSDAQ, Cadila Healthcare, Therapy, COVID-19, Vaccine, COVID 19, DNA, US, Organic acid, US FDA, Degenerative disease, EUA, Edwards Lifesciences, Technology transfer, COVID, Pharmaceutical industry, Enzychem, Zydus, ENZYCHEM, ZYDUS

Enzychem Lifesciences (KOSDAQ: 183490) and Cadila Healthcare Ltd, a part of the Zydus Group, today announced that they have entered a Manufacturing License and Technology Transfer Agreement for the worlds first plasmid DNA vaccine (ZyCoV-D).

Key Points: 
  • Enzychem Lifesciences (KOSDAQ: 183490) and Cadila Healthcare Ltd, a part of the Zydus Group, today announced that they have entered a Manufacturing License and Technology Transfer Agreement for the worlds first plasmid DNA vaccine (ZyCoV-D).
  • Under the terms of this agreement, Zydus shall transfer its manufacturing technology and provide technical assistance to Enzychem.
  • Both CHL and Enzychem believe that this partnership will lead to estimated manufacturing of 80 million or more doses of the plasmid DNA vaccine in 2022.
  • Mr. Ki Young Sohn, Chairman of Enzychem Lifesciences said: Today marks an important milestone for our vaccine consortium as we embark on the manufacturing of the worlds first- in-class DNA vaccine for humans.

PharmaJet Presents How to Improve Vaccine Performance with Needle-free Delivery at Vaccine World Asia Congress

Retrieved on: 
Monday, November 15, 2021
Biotechnology, Medical Devices, Infectious Diseases, Health, Pharmaceutical, Cadila Healthcare, Rabies, WHO, Injector, Vaccine, MBA, U.S. FDA, PQS, CE marking, Use, COVID-19, Research, Injection, Polio, Needle, LinkedIn, Solution, Therapy, R & D, Certification, Review, Vaccination, DNA, Feedback, MS, Pharmaceutical industry, PharmaJet, Zydus, PHARMAJET, ZYDUS

PharmaJet , the maker of innovative, needle-free injection technology, announced that their latest research results will be presented at the Vaccine World Asia Congress 2021 on November 17.

Key Points: 
  • PharmaJet , the maker of innovative, needle-free injection technology, announced that their latest research results will be presented at the Vaccine World Asia Congress 2021 on November 17.
  • The presentation, entitled Improving Vaccine Performance with Needle-free Delivery, is being presented by Paul LaBarre, MS, MBA, Vice President, Global Business Development.
  • The vaccine will be delivered exclusively with the PharmaJet Tropis Intradermal Needle-free Injection System.
  • PharmaJets mission is worldwide acceptance of PharmaJet needle-free devices as a standard of care in the vaccine delivery market.

Zydus receives EUA from DCGI for ZyCoV-D, the only needle-free COVID vaccine in the world

Retrieved on: 
Friday, August 20, 2021
National Institute of Virology, Population, Plasmid, Drugs Controller General of India, Immune system, Phase, DNA, DCGI, Indian Council of Medical Research, Disease, Cadila Healthcare, EUA, Adult, Volunteering, Immunity, Immunization, BIRAC, Emergency Use Authorization, COVID-19, Department, National Institute, Medical research, Vaccine, Pharmaceutical industry

ZyCoV-D is a three dose vaccine which will be administered first on day zero, day 28th and then on the 56th day.

Key Points: 
  • ZyCoV-D is a three dose vaccine which will be administered first on day zero, day 28th and then on the 56th day.
  • With this approval, India now has its first COVID-19 vaccine for the adolescents in the 12-18 age group, besides the adult population.
  • ZyCoV-D, is a needle-free vaccine administered using The PharmaJet a needle free applicator, which ensures painless intradermal vaccine delivery.
  • This is for the first time that a technologically advanced vaccine has been successfully developed on the Plasmid DNA platform for human use.